Method for treating muscular dystrophy using antagonist antibodies against GDF-8
The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.
1. A method of treating muscular dystrophy in a mammal, comprising administering to a mammal in need of treatment for muscular dystrophy a therapeutically effective amount of a GDF-8 specific antibody or antigen binding fragment thereof, said antibody or fragment comprising:
an antibody variable heavy (VH) domain having a first CDR comprising the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:20, a second CDR comprising the amino acid sequence of SEQ ID NO:11 or SEQ ID NO:21, and a third CDR comprising the amino acid sequence of SEQ ID NO:12; and
an antibody variable light (VL) domain having a first CDR comprising the amino acid sequence of SEQ ID NO:13, a second CDR comprising the amino acid sequence of SEQ ID NO:14, and a third CDR comprising the amino acid sequence of SEQ ID NO:15.
2. The method of claim 1 , wherein the VH domain of said antibody or fragment comprises the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7.
3. The method of claim 1 , wherein the VL domain of said antibody or fragment comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:9.
4. The method of claim 1 , wherein the VH domain of said antibody or fragment comprises the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7 and the VL domain of said antibody or fragment comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:9.
5. The method of claim 1 , wherein said antibody or fragment further comprises an antibody constant heavy (CH) domain from a human immunoglobulin subtype selected from the group consisting IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgE and IgM.
6. The method of claim 5 , wherein the CH domain of said antibody or fragment is modified to alter a constant domain effector function.
7. The method of claim 5 , wherein said antibody or fragment further comprises the heavy chain constant domains of the amino acid sequence of SEQ ID NO:19.
8. The method of claim 7 , wherein the amino acid sequence of SEQ ID NO:19 is modified at least at residue 117 or 120 thereof to alter an Fc region effector function.
9. The method of claim 1 , wherein said antibody or fragment further comprises a human antibody kappa or lambda constant light (CL) domain.
10. The method of claim 9 , wherein said CL domain comprises the amino acid sequence of SEQ ID NO:17.
11. A method of treating muscular dystrophy in a mammal, comprising administering to a mammal in need of treatment for muscular dystrophy a therapeutically effective amount of a GDF-8 specific antibody or antigen binding fragment thereof, said antibody or fragment comprising:
two antibody heavy chains, each comprising a variable heavy domain defined by the amino acid sequence of SEQ ID NO:7 and the heavy chain constant domains from human IgG1; and
two antibody light chains, each comprising a variable light domain defined by the amino acid sequence of SEQ ID NO:9 and a constant light domain defined by the amino acid sequence of SEQ ID NO:17.
12. A method of treating muscular dystrophy in a mammal, comprising administering to a mammal in need of treatment for muscular dystrophy a therapeutically effective amount of a GDF-8 specific antibody or antigen binding fragment thereof, said antibody or fragment consisting essentially of:
two antibody heavy chains, each consisting essentially of the variable heavy domain of the amino acid sequence of SEQ ID NO:7 joined with the heavy chain constant domains from human IgG1; and
two antibody light chains, each consisting essentially of the variable light domain of the amino acid sequence of SEQ ID NO:9 joined with the constant light domain of the amino acid sequence of SEQ ID NO:17.
13. The method of claim 1 , wherein said antibody or fragment is partially or fully humanized.
14. The method of claim 1 , wherein said antibody binds to GDF-8 with an affinity of about 10 nM or higher.
15. The method of claim 1 , wherein said muscular dystrophy is Duchenne's muscular dystrophy.
16. The method of claim 1 , wherein the VH domain of said antibody or fragment comprises the amino acid sequence of SEQ ID NO:7 and the VL domain of said antibody or fragment comprises the amino acid sequence of SEQ ID NO:9.